0(0%) Volume: 499,583 3:15AM EST| Market Cap : 5.16 B | Enterprise Value : 4.47 B | P/E (TTM) : | P/B : 7.08 |
|---|
NAS:ASND has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NAS:ASND has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Ascendis Pharma A/S's enterprise value is $4,471.19 Mil. Ascendis Pharma A/S's EBITDA for the trailing twelve months (TTM) ended in Sep. 2019 was $-175.66 Mil. Therefore, Ascendis Pharma A/S's EV-to-EBITDA for today is -25.45.
During the past 8 years, the highest EV-to-EBITDA of Ascendis Pharma A/S was -3.60. The lowest was -31.20. And the median was -11.45.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2019-12-11), Ascendis Pharma A/S's stock price is $108.00. Ascendis Pharma A/S's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2019 was $-4.26. Therefore, Ascendis Pharma A/S's PE Ratio for today is .
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.
| Ascendis Pharma A/S Quarterly Data | ||||||||||||||||||||
| Dec14 | Mar15 | Jun15 | Sep15 | Dec15 | Mar16 | Jun16 | Sep16 | Dec16 | Mar17 | Jun17 | Sep17 | Dec17 | Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | |
| EV-to-EBITDA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
-16.23 | -16.11 | -29.46 | -24.94 | -22.28 |
* The bar in red indicates where Ascendis Pharma A/S's EV-to-EBITDA falls into.
Ascendis Pharma A/S's EV-to-EBITDA for today is calculated as:
| EV-to-EBITDA | = | Enterprise Value (Today) | / | EBITDA (TTM) |
| = | 4471.192 | / | -175.658602252 | |
| = | -25.45 |
Ascendis Pharma A/S's current Enterprise Value is $4,471.19 Mil.
Ascendis Pharma A/S's EBITDA for the trailing twelve months (TTM) ended in Sep. 2019 was -36.1126279863 (Dec. 2018 ) + -59.002259887 (Mar. 2019 ) + -55.3344632768 (Jun. 2019 ) + -25.2092511013 (Sep. 2019 ) = $-175.66 Mil.
* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Ascendis Pharma A/S's PE Ratio for today is calculated as:
| PE Ratio | = | Share Price (Today) | / | Earnings per Share (Diluted) (TTM) |
| = | 108.00 | / | -4.26187864766 | |
| = |
Ascendis Pharma A/S's share price for today is $108.00.
Ascendis Pharma A/S's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2019 was -0.864618885097 (Dec. 2018 ) + -1.4011299435 (Mar. 2019 ) + -1.41242937853 (Jun. 2019 ) + -0.583700440529 (Sep. 2019 ) = $-4.26.
* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Please read Which price ratio outperforms the enterprise multiple?
No Headline
Excel Add-In GURUF
API
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
My Gurus
Email Alerts
Stock PDF
RSS
Website
Filings
Manual of Stocks™ Web APP